Equities

Jagsonpal Pharmaceuticals Ltd

JAGSNPHARM:NSI

Jagsonpal Pharmaceuticals Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)410.15
  • Today's Change3.15 / 0.77%
  • Shares traded25.63k
  • 1 Year change-3.23%
  • Beta1.7302
Data delayed at least 15 minutes, as of Sep 20 2024 10:59 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of INR
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments1,4791,146471
Total Receivables, Net157249156
Total Inventory170236297
Prepaid expenses141111
Other current assets, total1733.15156
Total current assets1,9931,6461,091
Property, plant & equipment, net93243226
Goodwill, net--00.30
Intangibles, net------
Long term investments5238291
Note receivable - long term123.1211
Other long term assets212024
Total assets2,1711,9491,642
LIABILITIES
Accounts payable76164186
Accrued expenses7.523.764.90
Notes payable/short-term debt000
Current portion long-term debt/capital leases147.540
Other current liabilities, total9410179
Total current liabilities191276270
Total long term debt76520
Total debt89600
Deferred income tax212232
Minority interest------
Other liabilities, total9.181113
Total liabilities297361315
SHAREHOLDERS EQUITY
Common stock132131131
Additional paid-in capital1116.006.00
Retained earnings (accumulated deficit)1,6311,4511,112
Treasury stock - common------
Unrealized gain (loss)--00
Other equity, total00.8779
Total equity1,8741,5891,328
Total liabilities & shareholders' equity2,1711,9491,642
Total common shares outstanding262626
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.